CR7660A - DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE - Google Patents
DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSEInfo
- Publication number
- CR7660A CR7660A CR7660A CR7660A CR7660A CR 7660 A CR7660 A CR 7660A CR 7660 A CR7660 A CR 7660A CR 7660 A CR7660 A CR 7660A CR 7660 A CR7660 A CR 7660A
- Authority
- CR
- Costa Rica
- Prior art keywords
- composition
- hours
- average
- pramipexole
- absorption
- Prior art date
Links
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title abstract 4
- 239000002552 dosage form Substances 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229960003089 pramipexole Drugs 0.000 abstract 3
- 229940098778 Dopamine receptor agonist Drugs 0.000 abstract 1
- 238000007922 dissolution test Methods 0.000 abstract 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a una composicion farmaceutica administrable oralmente que comprende una cantidad terapeuticamente eficaz de pramipexol o una de sus sales farmaceuticamente aceptable y al menos un excipiente farmaceuticamente aceptable, presentando dicha composicion al menos (a) un perfil de liberacion in vitro en el que en promedio no mas de 20% aproximadamente de pramipexol se disuelve en 2 horas despues de la colocacion de la composicion de ensayo de disolucion convencional, y (b) un perfil de absorcion de pramipexol in vivo despues de la administracion oral de una dosis a humanos adultos sanos, donde el tiempo para alcanzar una media de 20% de absorcion es mayor que 2 horas aproximadamente y/o el tiempo para alcanzar una media de 40% de absorcion es mayor que 4 horas aproximadamente. La composicion es util para administrarse oralmente no mas de una vez al dia a un sujeto que tenga una condicion o desorden para el cual sea indicado un agonista receptor de dopamina.It refers to an orally administrable pharmaceutical composition comprising a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition having at least (a) an in vitro release profile in which on average no more than about 20% of pramipexole dissolves in 2 hours after the placement of the conventional dissolution test composition, and (b) an absorption profile of pramipexole in vivo after oral administration of a dose to healthy adult humans , where the time to reach an average of 20% absorption is greater than about 2 hours and / or the time to reach an average of 40% absorption is greater than about 4 hours. The composition is useful for oral administration no more than once a day to a subject who has a condition or disorder for which a dopamine receptor agonist is indicated.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39842702P | 2002-07-25 | 2002-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR7660A true CR7660A (en) | 2005-06-08 |
Family
ID=38181237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR7660A CR7660A (en) | 2002-07-25 | 2005-01-24 | DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE |
Country Status (2)
| Country | Link |
|---|---|
| CR (1) | CR7660A (en) |
| TN (2) | TNSN05019A1 (en) |
-
2005
- 2005-01-24 CR CR7660A patent/CR7660A/en not_active Application Discontinuation
- 2005-01-25 TN TNP2005000019A patent/TNSN05019A1/en unknown
- 2005-01-25 TN TNP2005000020A patent/TNSN05020A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN05019A1 (en) | 2007-05-14 |
| TNSN05020A1 (en) | 2007-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040682A1 (en) | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL | |
| ES2577930T3 (en) | Triazine derivatives to delay the onset of type 1 diabetes | |
| JP6659072B2 (en) | Melatonin agonist treatment | |
| AR040681A1 (en) | COMPOSITION OF PRAMIPEXOL SUSTAINED RELEASE TABLETS | |
| AR045972A1 (en) | FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS | |
| BR112019025286A2 (en) | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPING | |
| AR062320A1 (en) | FLIBANSERIN FORMULATIONS AND METHOD TO MANUFACTURE THEM | |
| UY27627A1 (en) | AZA - ARILPIPERAZINAS | |
| SE0203065D0 (en) | Gastric acid secretion inhibiting composition | |
| FI3504187T3 (en) | Use of pridopidine for treating functional decline | |
| AR066420A1 (en) | PHARMACEUTICAL COMPOSITION SUPPLY ORONASOPHARINGELY FOR THE PREVENTION OF RELIEF / AND OR TREATMENT OF DISORDERS OF UNQUIRED MEMBERS. USE. | |
| AR040709A1 (en) | FORMULATION OF LAMOTRIGIN FOR LONG-TERM RELEASE AND USE OF THE SAME FOR PREPARATION | |
| NO20073403L (en) | Use of atazanavir to improve the pharmacokinetics of drugs metabolized by UGT1A1 | |
| ECSP10010052A (en) | GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN | |
| AR058163A1 (en) | EXHALTING DRUGS OF SEXUAL DESIRE THAT INCLUDE DERIVATIVES OF BENZIMIDAZOLONA | |
| ATE505203T1 (en) | PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN | |
| CO6150126A2 (en) | FORMULATIONS OF IMMEDIATE RELEASE TABLETS FROM A TROMBINE RECEIVER ANTAGONIST | |
| AR066924A1 (en) | FORMULATION OF NEVIRAPINE OF PROLONGED RELEASE | |
| JP2007509146A5 (en) | ||
| UY27679A1 (en) | AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL AND FARINGIAN CAVITY. | |
| IL272834B2 (en) | Compositions of amantadine, their preparation, and methods of use | |
| CR7660A (en) | DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE | |
| HUP0400495A2 (en) | Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue | |
| PE20050086A1 (en) | PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT AND SODIUM BICARBONATE | |
| CO5680422A2 (en) | DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC90 | Suspension of granting procedure |